Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Connect Biopharma Holdings Limited filings document regulatory disclosures for a Cayman Islands clinical-stage biopharmaceutical issuer developing rademikibart for inflammatory diseases. Recent Form 8-K reports cover operating and financial results, clinical and regulatory updates tied to rademikibart, and Regulation FD disclosures.
The filing record also includes governance and capital-structure matters, including board composition, insider purchase disclosures, material agreements, ADR-program and deposit-agreement disclosures, and the relationship between American depositary shares and ordinary shares. These filings frame the company’s emerging-growth-company status, public-company reporting obligations and risk-related clinical development disclosures.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of Connect Biopharma Holdings Limited Ordinary Shares on a Schedule 13G/A. Through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, they report beneficial ownership of 4,338,534 Ordinary Shares, representing 6.9% of the class.
The percentage is based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. Ikarian Capital, as investment manager and sub-adviser, and Mr. Shahrestani, as its indirect controlling person, may be deemed to share voting and dispositive power over these shares, but each Reporting Person expressly disclaims beneficial ownership and membership in any group beyond what may be deemed under Section 13(d) or 13(g).
Connect Biopharma Holdings Ltd received an amended Schedule 13G from Wei Zheng reporting a beneficial ownership position in the company’s ordinary shares. Wei Zheng reports beneficial ownership of 2,520,359 ordinary shares, representing 4% of the class, with sole voting and dispositive power over all of these shares and no shared power. The percentage is based on 62,974,309 ordinary shares outstanding as disclosed in Connect Biopharma’s Form 10-Q for the period ended June 30, 2026.
Connect Biopharma Holdings Limited, a clinical-stage company focused on asthma and COPD, reported higher collaboration revenue but larger losses for the three and six months ended June 30, 2026. License and collaboration revenue rose to $2.8 million for the quarter and $2.9 million year‑to‑date, driven mainly by a regulatory milestone from the Simcere Greater China partnership, partially offset by development cost sharing.
Research and development expense increased to $16.3 million for the quarter and $31.3 million year‑to‑date, reflecting expanded rademikibart clinical programs in acute asthma and COPD. General and administrative expense declined to $4.1 million for the quarter and $8.8 million year‑to‑date, primarily from lower professional fees.
The company recorded a net loss of $17.3 million for the quarter and $36.7 million for the first half of 2026, with operating cash outflows of $31.9 million. Cash, cash equivalents and short‑term investments totaled $31.5 million as of June 30, 2026, including net proceeds of $18.6 million from a March 2026 private placement of 6,130,000 ordinary shares. Management believes these resources will meet anticipated cash requirements for at least one year from the report filing date.
Connect Biopharma Holdings Limited reported second-quarter 2026 results and clinical progress for rademikibart in asthma and COPD. Enrollment was completed in the Phase 2 Seabreeze STAT asthma and COPD studies, with topline data expected in September 2026, and a new Phase 2 Seabreeze STAT IV study was initiated in August 2026.
For the quarter ended June 30, 2026, license and collaboration revenues were $2.8 million, largely from a regulatory milestone under the Simcere license, versus $48,000 a year earlier. Research and development expense rose to $16.3 million, and general and administrative expense was $4.1 million. Net loss was $17.3 million, or ($0.27) per share, compared with $12.9 million, or ($0.23) per share, in 2025.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled $31.5 million, and the company believes this will fund operations for at least one year from the release date. Under its Simcere agreement, Connect remains eligible for up to approximately $99 million in additional milestone payments plus tiered royalties on Greater China net sales.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 3,738 Ordinary Shares of the company on June 30, 2026. These fully vested shares were issued at no cash cost to him in lieu of a portion of his 2026 annual board cash retainers for service during the second quarter of 2026.
After this equity award, he directly holds 86,554 Ordinary Shares of Connect Biopharma. The number of shares granted was determined by dividing the elected cash amount by the average closing price of the company’s ordinary shares over the 30 days preceding June 30, 2026, rounded down to the nearest whole share.
Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant as board compensation. She acquired 6,718 ordinary shares at no cash cost, issued as fully vested shares in lieu of cash retainers for her 2026 annual board service during the second quarter of 2026.
After this award, she directly holds 11,779 ordinary shares. The number of shares granted was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares for the 30 days preceding June 30, 2026, then rounding down to the nearest whole share.
Connect Biopharma Holdings Ltd reported an insider-related open-market purchase of its Ordinary Shares. An entity associated with director James Huang, Panacea Venture Healthcare Fund II, L.P., bought 150,000 Ordinary Shares at a weighted average price of $2.4774 per share.
After this transaction, the entity indirectly associated with Huang held 13,310,000 Ordinary Shares. The shares were purchased in multiple trades between $2.37 and $2.52, and Huang disclaims beneficial ownership despite being associated with the fund’s control structure.
Connect Biopharma Holdings Ltd reports that Wei Zheng beneficially owns 3,876,036 ordinary shares, representing 6.2% of the class. The percentage is calculated using 56,521,282 Ordinary Shares outstanding as of March 26 and the 6,130,000 Ordinary Shares issued in the Offering disclosed on March 30, 2026.
The filing attributes sole voting and dispositive power over the 3,876,036 shares to Wei Zheng. The report updates prior Schedule 13G holdings and provides the ownership stake as of the cited disclosure dates.
Connect Biopharma filed a Form F-3 shelf prospectus to register the resale of up to 6,130,000 Ordinary Shares, par value $0.000174 per share, held by selling securityholders. The shares were issued in a private placement that closed on March 31, 2026 at $3.25 per share; the company will not receive proceeds from resales. The prospectus states the selling securityholders may sell the shares from time to time on Nasdaq or in private transactions under the described Plan of Distribution. The prospectus discloses 62,963,853 Ordinary Shares outstanding as of April 30, 2026 and notes Nasdaq symbol CNTB with a last reported sale price of $2.48 per share on May 14, 2026.